Over the past six months, Benitec Biopharma's stock (BNTC) has experienced fluctuations, including a decline of 6.67% from September 10, 2025, to September 9, 2026, and a recent increase of 17.83% in the month leading up to August 21, 2026. However, as of September 18, 2026, the stock price was $10.99, reflecting a -3.34% move since market open, a -9.58% decrease compared to the previous week, a -16.67% fall over the last month, and a -25.79% decrease over the last year. Key events impacting the stock include the release of third-quarter 2026 financial results and an operational update on May 14, 2026. On April 28, 2026, the company announced an oral presentation of interim Phase 1b/2a clinical study results for high-dose BB-301, showing continued durable improvements for low-dose BB-301, at the 2026 American Society of Gene and Cell Therapy Annual Meeting. Benitec Biopharma hosted an Industry Forum Breakfast Event on March 10, 2026. On September 14, 2026, the company announced its full fiscal year ended June 30, 2026, financial results, reporting a net loss of $45.5 million and approximately $180 million in cash and cash equivalents, alongside updates on regulatory interactions and upcoming clinical data presentations, including the completion of 12-month follow-up for all six Cohort 1 (low dose BB-301) patients and full enrollment of Cohort 2 (high dose BB-301). A Type C meeting with the U.S. Food and Drug Administration was held in Q3 2026 to discuss the BB-301 pivotal study design, with minutes anticipated in October. Additionally, interim clinical study results from the BB-301 Phase 1b/2a trial have been accepted for late-breaking presentation at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany, from October 27-30, 2026.
